Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

10.88 -2.45 (-18.36%)
Streaming Delayed Price Updated: 12:25 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,384,647
Open 12.78
Bid (Size) 10.86 (2)
Ask (Size) 10.89 (2)
Prev. Close 13.32
Today's Range 10.47 - 12.97
52wk Range 12.24 - 150.48
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit

Performance

YTD
-91.2%
-91.2%
1 Month
-42.4%
-42.4%
3 Month
-81.7%
-81.7%
6 Month
-90.6%
-90.6%
1 Year
-92.6%
-92.6%

More News

Read More
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Is This Stock a Buy After Soaring by 20% in 1 Day?
Via The Motley Fool
Topics Death
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
Via Stocktwits
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours
Via Stocktwits
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Via NewMediaWire
Topics Fraud Lawsuit
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division
Via Benzinga
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys
Via Investor's Business Daily
Topics Death ETFs
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review
Via Benzinga
Agilysys Posts Downbeat Earnings, Joins NXP Semiconductors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets
Via Benzinga
Sarepta Topples, Again, After Refusing The FDA's Request To Pull Elevidys
Via Investor's Business Daily
Topics Death Government
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Get insights into the top gainers and losers of Monday's pre-market session.
Via Chartmill

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 10.88
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 07/24/25 12:25 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.01B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.